Diagnostic value of peripheral blood markers for acute rejection in liver transplanted-patients receiving anti IL-2R antibodies

LaboratoriumsMedizin

Volumn 32, Issue 3, 2008, Pages 148-157

  Weimann, Andreas ^a,e   Eisele, Robert M ^a   Pawellek, Sebastian ^a   Hippler Benscheid, Michael ^a   Rüggeberg, Anne ^a   Cammann, Henning ^a   Radke, Cornelia ^b   Müller, Christian ^a   Klupp, Jochen ^a   Sack, Ulrich ^c,d   Lun, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Red Cross Hospital   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Acute rejection; Basiliximab; Diagnostic markers; Liver transplantation; T cell markers

Indexed keywords

ALANINE AMINOTRANSFERASE; BASILIXIMAB; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD28 ANTIGEN; CHOLESTEROL; CYCLOSPORIN A; DIPEPTIDYL PEPTIDASE IV; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 8; METHYLPREDNISOLONE; PREDNISOLONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EXAMINATION; DIAGNOSTIC VALUE; EOSINOPHIL COUNT; FEMALE; GRAFT FAILURE; GRAFT INFECTION; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTHROMBIN TIME; T LYMPHOCYTE ACTIVATION; YOUDEN INDEX;

EID: 44949108395     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2008.031     Document Type: Article

References (44)

1. Ayres R, Adams D. Acute rejection of human liver allografts. In: Neuberger J, Adams D, editors. Immunology of liver transplantation. London: Edward Arnold 1993:197-215.
2. Henley KS, Lucey MR, Appelman HD, Baliga P, Brown KA, Burtch GD, et al. Biochemical and histopathological correlation in liver transplant: the first 180 days. Hepatology 1992;16:688-93.
3. Clouston AD, Walker NI, Balderson GA, Lynch SV, Strong RW. Outcomes of rejection in adult liver transplant recipients - the Queensland experience. Transplant Proc 1993;25:2886-7.
4. Dousset B, Hubscher SG, Padbury RT, Gunson BK, Buckels JA, Mayer AD, et al. Acute liver allograft rejection - is treatment always necessary? Transplantation 1993;55:529-34.
5. Abraham SC, Furth EE. Receiver operating characteristic analysis of serum chemical parameters as tests of liver transplant rejection and correlation with histology. Transplantation 1995;59:740-6.
6. Trull AK, Facey SP, Rees GW, Wight DG, Noble-Jamieson G, Joughin C, et al. Serum alpha-glutathione S-transferase - a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. Transplantation 1994;58:1345-51.
7. Hickman PE, Lynch SV, Potter JM, Walker NI, Strong RW, Clouston AD. Gamma glutamyl transferase as a marker of liver transplant rejection. Transplantation 1994;57:1278-80.
8. Nagral A, Butler P, Sabin CA, Rolles K, Burroughs AK. Alpha-glutathione-S-transferase in acute rejection of liver transplant recipients. Transplantation 1998;65:401-5.
9. Hughes VF, Trull AK, Joshi O, Alexander GJ. Monitoring eosinophil activation and liver function after liver transplantation. Transplantation 1998;65:1334-9.
10. Lun A, Cho MY, Muller C, Staffa G, Bechstein WO, Radke C, et al. Diagnostic value of peripheral blood T-cell activation and soluble IL-2 receptor for acute rejection in liver transplantation. Clin Chim Acta 2002;320:69-78.
11. Lohmann R, Langrehr JM, Klupp J, Jonas S, Raakow R, Bechstein WO, et al. Infectious complications after orthotopic liver transplantation with different immunosuppressive induction regimens. Transplant Proc 2000;32:537-8.
12. Nashan B, Light S, Hardie IR, Lin A, Johnson JR. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999;67:110-5.
13. Neuhaus P, Keck H, Bechstein WO, Blumhardt G, Langrehr JM, Wiens M, et al. Quadruple induction immunosuppression after liver transplantation with IL-2 receptor antibody (BT 563) is equally effective and better tolerated than ATG induction therapy. Transplant Proc 1993;25:587-9.
14. Dang NH, Torimoto Y, Shimamura K, Tanaka T, Daley JF, Schlossman SF, et al. 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol 1991;147:2825-32.
15. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989;86:1333-7.
16. Neuhaus P, Bechstein WO, Blumhardt G, Wiens M, Lemmens P, Langrehr JM, et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993;55:1320-7.
17. Anonymous: Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658-63.
18. Salcedo M, Hoglund P, Ljunggren HG. Natural killer cell interaction with murine allogeneic MHC class I molecules. Transplantation 1995;60:281-6.
19. Keller, T. Multiples Testen. http://acomed-statistik.de/multtest.html.
20. Fluss R, Faraggi D, Reiser B. Estimation of the Youden index and its associated cutoff point. Biom J 2005;47:458-72.
21. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34.
22. Krafft J, Fink R, Rosalki SB. Serum enzymes and isoenzymes after surgery. Ann Clin Biochem 1977;14:294-6.
23. Nicholson G, Bryant AE, Macdonald IA, Hall GM. Osteocalcin and the hormonal, inflammatory and metabolic response to major orthopaedic surgery. Anaesthesia 2002;57:319-25.
24. Warle MC, Kwekkeboom J, Tilanus HW, Metselaar HJ. Basiliximab interferes with the detection of soluble IL-2 receptor by the Immulite immunoassay system. J Immunol Methods 2003;275:133-6.
25. Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF. A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci (Lond) 2000;99:93-104.
26. Minguela A, Marin L, Torio A, Muro M, Garcia-Alonso AM, Moya-Quiles MR, et al. CD28/CTLA-4 and CD80/CD86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant. Hum Immunol 2000;61:658-69.
27. Minguela A, Garcia-Alonso AM, Marin L, Torio A, Sanchez-Bueno F, Bermejo J, et al. Evidence of CD28 upregulation in peripheral T-cells before liver transplant acute rejection. Transplant Proc 1997;29:499-500.
28. Davenport M, Gonde C, Redkar R, Koukoulis G, Tredger M, Mieli-Vergani G, et al. Immunohistochemistry of the liver and biliary tree in extrahepatic biliary atresia. J Pediatr Surg 2001;36:1017-25.
29. Crosbie OM, Norris S, Hegarty JE, O'Farrelly C. T lymphocyte subsets and activation status in patients following liver transplantation. Immunol Invest 1998;27:237-41.
30. Nakajima Y, Hisanaga M, Taki J, Kanehiro H, Nakano H. Cytoimmunologic monitoring using DNA analysis in canine liver transplantation. Transplantation 1993;55:480-3.
31. Döcke WD, Reinke P, Staffa G, Settmacher U, Höger T, Groth J, et al. An immune monitoring program for the management of immunosuppressive therapy in early phase after transplantation. Transplant Med 1994;6:13-28.
32. Jindal RM, Greer G, Popescu I, Sidner RA. Lymphocyte subset analysis for the diagnosis of rejection and infection in recipients of liver transplants. Am Surg 1999;65:77-80.
33. Perdigoto R, Paiva A, Freitas A, Coimbra HB, Mota O, Ferrao J, et al. Peripheral blood lymphocyte phenotype can predict rejection episodes after orthotopic liver transplantation. Transplant Proc 1999;31:2418-20.
34. Pross M, Manger T, Weiss G, Lippert H, König W, Kunz D. Die diagnostische Wertigkeit von Procalcitonin und IL-6 in Kombination mit dem zellulären Immunstatus für das therapeutische Management nach Lebertransplantation. Tex Med 1998;100:195-201.
35. Crosbie OM, Costello PJ, O'Farrelly C, Hegarty JE. Changes in peripheral blood double-negative T-lymphocyte(CD3+ CD4- CD8-) populations associated with acute cellular rejection after liver transplantation. Liver Transpl Surg 1998;4:141-5.
36. Lautenschlager I, von Willebrand E, Hayry P. Blood eosinophilia, steroids, and rejection. Transplantation 1985;40:354-7.
37. Trull AK, Akhlaghi F, Charman SC, Endenberg S, Majid O, Cornelissen J, et al. Immunosuppression, eotaxin and the diagnostic changes in eosinophils that precede early acute heart allograft rejection. Transpl Immunol 2004;12:159-66.
38. Trull AK, Steel LA, Sharples LD, Akhlaghi F, Parameshwar J, Cary N, et al. Randomized trial of blood eosinophil count monitoring as a guide to corticosteroid dosage adjustment after heart transplantation. Transplantation 2000;70:802-9.
39. Foster PF, Sankary H, Williams JW. Study of eosinophilia and hepatic dysfunction as a predictor of rejection in human liver transplantation. Transplant Proc 1988;20:676-7.
40. Dallman MJ. Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol 1995;7:632-8.
41. Russo FP, Bassanello M, Senzolo M, Cillo U, Burra P. TI - Functional and morphological graft monitoring after liver transplantation. Clin Chim Acta 2001;310:17-23.
42. Moia M, Martinelli I, Mannucci PM. TI - Laboratory measures of hemostasis for monitoring liver graft function. Semin Thromb Hemost 1993;19:238-42.
43. Tietge UJ, Boker KH, Bahr MJ, Weinberg S, Pichlmayr R, Schmidt HH, et al. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998;45:2255-60.
44. Ishida H, Furusawa M, Ishizuka T, Tojimbara T, Nakajima I, Fuchinoue S, et al. Short-term changes in cholesterol metabolism in 40 patients with liver transplants from living related donors. Transpl Int 2002;15:142-4.